Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
| ▸ | Q9HBH1 | 1/20 | 0.36 | |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 6/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7707870 | 0.84 | BMP1 (0.49) | GNPATSIRT5MMP1 | |
| SCHEMBL9700817 | 0.82 | GNPAT (0.41) | GNPATCTSSCTSKMMP3 | |
| SCHEMBL29973263 | 0.81 | GNPAT (0.65) | GNPATSIRT6SIRT1SIRT5PDF | |
| SCHEMBL4599095 | 0.78 | SMN1; SMN2 (0.38) | GNPAT | |
| SCHEMBL3381661 | 0.78 | SMN1; SMN2 (0.38) | GNPAT | |
| SCHEMBL31615759 | 0.77 | GNPAT (0.59) | GNPATSIRT6SIRT1CTSSCTSK | |
| SCHEMBL31615037 | 0.77 | GNPAT (0.59) | GNPATSIRT6SIRT1CTSSCTSK | |
| SCHEMBL31615880 | 0.77 | GNPAT (0.59) | GNPATSIRT6SIRT1CTSSCTSK | |
| SCHEMBL19546728 | 0.76 | SIRT6 (0.53) | GNPATSIRT6SIRT1CTSSCTSK | |
| SCHEMBL15539031 | 0.76 | CTSS (0.49) | SIRT6SIRT1CTSSCTSKMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | GNPAT 2708/4885SIRT6 3067/4885SIRT1 3118/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | GNPAT 3214/4885SIRT6 3792/4885SIRT1 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.